Only 2 Drugs Retevmo Selpercatinib and Gavreto Pralsetinib Have been Approved Till now In 2020
“Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026” Report Highlights:
- Global RET Inhibitors Market Opportunity: > USD 1.5 Billion
- Global RET Inhibitors Market Absolute Growth : 3900% (2020-2026)
- RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase
- RET Inhibitors In Clinical Trials: > 15 Drugs
- Commercially Available RET Inhibitors: 2 (Retevmo and Gavreto)
- First RET Inhibitor Approved In 2020: Retevmo
The advancement made by science and innovation in last few decades has enabled the identification of several potential targets which have a critical role in the pathogenesis of cancer and can be further used in the drug development process. The detection of rearranged during transfection (RET) arrangements in a variety of human cancers including thyroid, lung, colorectal, breast, and salivary gland cancers has opened up new opportunities in cancer therapeutics.
The RET proto-oncogene encodes a receptor-type tyrosine kinase with an extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The extensive research and development activities by the researchers have led to the development of novel RET inhibitors which are used in the management of cancer. Currently, two RET inhibitors namely Retemvo and Gavetro have been approved by FDA for the management of thyroid as well as non-small cell lung cancer.
Historically, chemotherapy as well as radiotherapy was the mainstay treatment options available for RET positive tumors, but the advent of targeted RET inhibitors have revolutionized the paradigm of cancer treatment. These RET inhibitors confer several advantages over previously approved therapies in terms of targetability, specificity and efficacy. Moreover, these drugs are not associated with side effects in comparison to conventional therapies and have greatly improved the survival rates in patients.
The global RET inhibitor market is following a trajectory path which is mainly due to increase in burden of cancer and the unmet need for the development of novel targeted cancer therapies. Furthermore, RET inhibitors are expected to grow at high rate during the forecast period due to their advantages over already approved therapies. In addition to this, the robust clinical pipeline of the RET inhibitors are also going to boost the growth of the market. Despite several advantages of RET inhibitors in management of cancer, there are several factors which restrains the growth of market. The resistance to the drugs during 1-2 year of the therapy is one of the limiting factors which will act as a barrier to the market. Moreover, the high cost associated with the drug will also limit the availability of the drug and increases the financial toxicity on the patient and their families.
Presently, US holds the top position in the market and is expected to maintain its position during the forecast period due to to the presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing funding by the government to promote research and development. In addition to this, the rise in prevalence of cancer and the increase awareness for the acceptance of novel therapies is also going to drive the future of the market. Moreover, the global market will be driven the rising approval of these drugs in other regions such as Europe, China and Asia and their increasing applications in other cancers.
The report RET inhibitor market provides information on the price, dosage and sales of the currently approved drugs as well as the emerging novel RET inhibitors in the market. Moreover, the report also provides clinical insights into the ongoing clinical trials by phase, status and region. Furthermore, the report also predicts future potential of RET inhibitors in the market by analyzing the current market as well as its dynamics.